<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11286466</article-id><article-id pub-id-type="pmc">2363838</article-id><article-id pub-id-type="pii">6691716</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1716</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kawata</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yamasaki</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nagase</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inui</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsuda</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tamura</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Noda</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan</aff><aff id="aff2"><label>2</label>Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, 990-9585, Japan</aff><pub-date pub-type="ppub"><month>04</month><year>2001</year></pub-date><volume>84</volume><issue>7</issue><fpage>886</fpage><lpage>891</lpage><history><date date-type="received"><day>22</day><month>02</month><year>2000</year></date><date date-type="rev-recd"><day>28</day><month>12</month><year>2000</year></date><date date-type="accepted"><day>19</day><month>01</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients &#x0003c;71 years old (mean age 62) with unresectable HCC were enroled in this study. 8 patients were withdrawn because of progressive liver dysfunction; 83 patients were randomized to standard treatment with or without pravastatin. All patients underwent transcatheter arterial embolization (TAE) followed by oral 5-FU 200&#x02008;mg<sup>&#x02212;1</sup>d for 2 months. Patients were then randomly assigned to control (<italic>n</italic> = 42) and pravastatin (<italic>n</italic> = 41) groups. Pravastatin was administered at a daily dose of 40&#x02008;mg. The effect of pravastatin on tumour growth was assessed by ultrasonography. Primary endpoint was death due to progression of HCC. The duration of pravastatin administration was 16.5 &#x000b1; 9.8 months (mean &#x000b1; SD). No patients in either group were lost to follow-up. Median survival was 18 months in the pravastatin group versus 9 months in controls (<italic>P</italic> = 0.006). The Cox proportional hazards model showed that pravastatin was a significant factor contributing to survival. Pravastatin prolonged the survival of patients with advanced HCC, suggesting its value for adjuvant treatment. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>hepatocellular carcinoma</kwd><kwd>pravastatin</kwd><kwd>HMG-CoA reductase inhibitor</kwd><kwd>survival</kwd></kwd-group></article-meta></front></article>


